Steven Cohen Taysha Gene Therapies, Inc. Transaction History

Point72 Asset Management, L.P.

$51 Billion
Q3 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 7,331,470 shares of TSHA stock, worth $30.9 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

7,331,470

Previous 7,317,614 0.19%

Holding current value

$30.9 Million

Previous $16.9 Million 36.63%

% of portfolio

0.05%

Previous 0.04%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$2.34 - $3.29 $32,423 - $45,586	13,856 Added 0.19%	7,331,470 $23.1 Million
Q2 2025 Aug 14, 2025	BUY	$1.13 - $2.9 $3.11 Million - $7.97 Million	2,747,936 Added 60.13%	7,317,614 $16.9 Million
Q1 2025 May 15, 2025	BUY	$1.39 - $2.05 $6.35 Million - $9.37 Million	4,569,678 New	4,569,678 $6.35 Million
Q1 2024 May 15, 2024	SELL	$1.43 - $3.25 $2.25 Million - $5.12 Million	-1,574,768 Reduced 58.59%	1,113,232 $3.19 Million
Q4 2023 Feb 14, 2024	BUY	$1.33 - $2.88 $2.33 Million - $5.04 Million	1,751,450 Added 187.01%	2,688,000 $4.76 Million

Q3 2023 Nov 14, 2023	BUY	$0.63 - $3.66 $590,026 - $3.43 Million	936,550 New	936,550 $2.96 Million
Q1 2021 May 17, 2021	SELL	$20.3 - $31.75 $271,329 - $424,370	-13,366 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$19.14 - $28.13 $3.57 Million - $5.25 Million	-186,634 Reduced 93.32%	13,366 $355,000
Q3 2020 Nov 16, 2020	BUY	$22.4 - $24.47 $4.48 Million - $4.89 Million	200,000 New	200,000 $4.48 Million

Others Institutions Holding TSHA

# of Institutions

161

Shares Held

247M

Call Options Held

463K

Put Options Held

246K

View Full List

About Taysha Gene Therapies, Inc.

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $204M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

More about TSHA

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account